Physician profile
Mark D Borchelt
NPI 1194776286
$722,268.14
in general payments reported to CMS, 2019-2025
63 companies · $63K in 2025
The $63K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $160K · 2020: $68K · 2021: $60K · 2022: $176K · 2023: $100K · 2024: $96K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Travel and Lodging: $38K · Honoraria: $19K · Food and Beverage: $19K · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,938.50 |
| Travel and Lodging | $37,700.58 |
| Honoraria | $19,012.50 |
| Food and Beverage | $18,854.89 |
| Education | $130.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $355,117.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $89,560.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Grt US Holding, INC. | $86,517.27 | 2020-2022 | |
| Amgen INC. | $57,282.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Averitas Pharma INC. | $27,211.60 | 2023-2025 | Qutenza |
| Corcept Therapeutics | $26,114.51 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,633.56 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $20,476.19 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,522.43 | 2021-2025 | |
| Clarus Therapeutics INC. | $7,990.41 | 2021 | |
| Abbott Laboratories | $3,700.70 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Medtronic, INC. | $2,738.13 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Astrazeneca Pharmaceuticals Lp | $1,452.22 | 2019-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $1,349.78 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Eli Lilly and Company | $1,288.59 | 2019-2023 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,074.11 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $1,035.42 | 2019-2024 | |
| Radius Health, INC. | $993.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $619.68 | 2019-2022 | |
| Insulet Corporation | $522.35 | 2019-2025 | Omnipod |
| Mannkind Corporation | $452.63 | 2019-2024 | |
| Beta Bionics, INC. | $431.95 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $309.15 | 2019-2025 | Ubrelvy |
| Becton, Dickinson and Company | $301.88 | 2019-2022 | |
| Medtronic Minimed, INC. | $282.25 | 2019-2020 | |
| Zealand Pharma US, INC. | $273.98 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $256.21 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Valeritas, INC. | $254.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $253.88 | 2023-2025 | |
| Amarin Pharma, INC. | $248.95 | 2019-2021 | |
| Ibsa Pharma INC. | $214.70 | 2019-2025 | Tirosint, Licart, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.07 | 2020-2023 | Cycloset |
| Recordati_rare_diseases_inc. | $175.79 | 2020-2025 | Isturisa, Signifor Lar |
| Lifescan, INC. | $166.44 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $165.83 | 2019-2024 | Evkeeza |
| Embecta Corp. | $115.50 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascendis Pharma Endocrinology INC | $78.23 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $74.81 | 2021-2025 | Nexletol |
| Vifor Pharma, INC. | $72.41 | 2021 | |
| Madrigal Pharmaceuticals | $69.39 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $64.14 | 2020-2021 | |
| Antares Pharma, INC. | $63.46 | 2020-2022 | |
| Almatica Pharma LLC | $61.55 | 2024-2025 | Teriparatide |
| Tolmar, INC. | $57.90 | 2023-2025 | Jatenzo |
| Ultragenyx Pharmaceutical INC. | $55.71 | 2020-2024 | Crysvita |
| Alfasigma USA, INC. | $48.36 | 2022 | |
| Amryt Pharma Holdings Ltd | $39.41 | 2022-2023 | Mycapssa |
| Acerus Pharmaceuticals Corporation | $35.89 | 2022 | |
| Kyowa Kirin, INC. | $25.65 | 2025 | |
| Shire North American Group INC | $25.53 | 2019 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Alvogen INC | $23.54 | 2025 | Teriparatide |
| Nevro Corp. | $22.86 | 2024 | Senza |
| Senseonics, Incorporated | $22.00 | 2019 | |
| Horizon Therapeutics Plc | $21.74 | 2021 | |
| Sequel Med Tech, LLC | $19.95 | 2025 | Twiist |
| Cequr Corporation | $18.20 | 2025 | Cequr Simplicity |
| Amphastar Pharmaceuticals, INC. | $17.80 | 2024 | Baqsimi |
| Ucb, INC. | $15.17 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,040.12 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Borchelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.